EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polygenic risk discriminates Lewy body dementia from Alzheimer's disease

Anna McKeever, Peter Swann, Maura Malpetti, Paul C Donaghy, Alan Thomas, Elijah Mak, Stephen F Carter, Jerry H K Tan, Young T Hong, Tim D Fryer, Amanda Heslegrave, Henrik Zetterberg und 4 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Anna McKeever und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease, Multifactorial Inheritance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University College London Hospitals Biomedical Research Centre, Familjen Rönströms Stiftelse, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Lewy body dementia (LBD) shares genetic risk factors with Alzheimer's disease (AD), including apolipoprotein E (APOE ), but is distinguishable at the genome‐wide level. Polygenic risk scores (PRS) may therefore improve diagnostic classification. METHODS We assessed diagnostic classification using AD‐PRS excluding APOE (AD‐PRS no APOE ), APOE risk score ( APOE ‐RS), and plasma phosphorylated tau 181 (p‐tau181), in 83 participants with LBD, 27 with positron emission tomography amyloid beta (Aβ)positive mild cognitive impairment or AD (MCI+/AD), and 57 controls. RESULTS Together AD‐PRS no APOE and APOE ‐RS performed similarly to p‐tau181 in discriminating MCI+/AD from controls (area under the curve 76% vs. 79%) and LBD (71% vs. 72%). In LBD, Aβ positivity was significantly associated with APOE‐ RS, but not with AD‐PRS no APOE , or p‐tau181. Combining AD‐PRS no APOE , APOE‐ RS, and p‐tau181 improved the discrimination of MCI+/AD from controls (81%) and LBD (75%), and the detection of Aβ in LBD (82%). DISCUSSION Aβ deposition in LBD was associated with APOE , while MCI+/AD was also associated with AD‐PRS beyond APOE . AD‐PRS explains phenotypic variance not captured by APOE or p‐tau181. Highlights We investigated Alzheimer's disease (AD) polygenic risk score (PRS), apolipoprotein E ( APOE ), and plasma phosphorylated tau 181 (p‐tau181) to classify AD and Lewy body dementia (LBD). AD‐PRS with APOE achieved similar classification accuracy to p‐tau181. AD‐PRS without APOE significantly contributed to discriminating AD from LBD. Amyloid beta positivity in LBD was associated with APOE but not AD‐PRS without APOE or p‐tau181. Combining AD‐PRS, APOE , and p‐tau181 improved diagnostic classification accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lewy Body DiseaseAlzheimer DiseaseMultifactorial InheritanceHumansMaleFemaleAgedtau ProteinsApolipoproteins EAmyloid beta-PeptidesCognitive DysfunctionPositron-Emission TomographyAged, 80 and overRisk FactorsDiagnosis, DifferentialGenetic Predisposition to Disease

Stichwörter der Autor:innen

Alzheimer's diseaseLewy body dementiaplasma biomarkersplasma phosphorylated taupolygenic risk score

Substanzen

tau ProteinsApolipoproteins EAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Department of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Förderung

  • University College London Hospitals Biomedical Research Centre
  • Familjen Rönströms Stiftelse
  • Swedish Research Council
  • Alzheimer's Drug Discovery Foundation
  • Lewy Body Society
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • AD Strategic Fund and the Alzheimer's Association
  • Erling-Perssons Stiftelse

Zitieren

APA

McKeever, A., Swann, P., Malpetti, M., Donaghy, P. C., Thomas, A., Mak, E., Carter, S. F., Tan, J. H. K., Hong, Y. T., Fryer, T. D., Heslegrave, A., Zetterberg, H., Su, L., Chouliaras, L., Rowe, J. B., & O'Brien, J. T. (2025). Polygenic risk discriminates Lewy body dementia from Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14381

Vancouver

McKeever A, Swann P, Malpetti M, Donaghy PC, Thomas A, Mak E, et al. Polygenic risk discriminates Lewy body dementia from Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14381

BibTeX
@article{McKeever2025,
  author = {McKeever, Anna and Swann, Peter and Malpetti, Maura and Donaghy, Paul C and Thomas, Alan and Mak, Elijah and Carter, Stephen F and Tan, Jerry H K and Hong, Young T and Fryer, Tim D and Heslegrave, Amanda and Zetterberg, Henrik and Su, Li and Chouliaras, Leonidas and Rowe, James B and O'Brien, John T},
  title = {Polygenic risk discriminates Lewy body dementia from Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14381}
}
Kostenlos starten →